-
公开(公告)号:US08735390B2
公开(公告)日:2014-05-27
申请号:US13821585
申请日:2011-09-06
申请人: Julie Nicole Hamblin , Paul Spencer Jones , Suzanne Elaine Keeling , Joelle Le , Charlotte Jane Mitchell , Nigel James Parr , Robert David Willacy
发明人: Julie Nicole Hamblin , Paul Spencer Jones , Suzanne Elaine Keeling , Joelle Le , Charlotte Jane Mitchell , Nigel James Parr , Robert David Willacy
IPC分类号: A61K31/5377 , C07D413/14
CPC分类号: A61K31/5377 , C07D413/14
摘要: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
摘要翻译: 本发明涉及作为激酶活性抑制剂的化合物的新型多晶型物和盐。
-
公开(公告)号:US20130165441A1
公开(公告)日:2013-06-27
申请号:US13821585
申请日:2011-09-06
申请人: Julie Nicole Hamblin , Paul Spencer Jones , Suzanne Elaine Keeling , Joelle Le , Charlotte Jane Mitchell , Nigel James Parr , Robert David Willacy
发明人: Julie Nicole Hamblin , Paul Spencer Jones , Suzanne Elaine Keeling , Joelle Le , Charlotte Jane Mitchell , Nigel James Parr , Robert David Willacy
IPC分类号: C07D413/14
CPC分类号: A61K31/5377 , C07D413/14
摘要: The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
-
3.6-(1H-indol-4-yl)-4-(5-{[4-1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole hemi succinate salt, polymorphs and pharmaceutical compositions thereof 有权
标题翻译: 6-(1H-吲哚-4-基)-4-(5 - {[4-1-甲基乙基] -1-哌嗪基]甲基} -1,3-恶唑-2-基)-1H-吲唑半琥珀酸盐 ,多晶型物及其药物组合物公开(公告)号:US08993576B2
公开(公告)日:2015-03-31
申请号:US13879667
申请日:2011-10-25
申请人: Julie Nicole Hamblin , Paul Spencer Jones , Suzanne Elaine Keeling , Joelle Le , Nigel James Parr , Robert David Willacy
发明人: Julie Nicole Hamblin , Paul Spencer Jones , Suzanne Elaine Keeling , Joelle Le , Nigel James Parr , Robert David Willacy
IPC分类号: A61K31/496 , C07D413/14
CPC分类号: C07D413/14
摘要: The present invention is directed to a polymorph of a compound and salts of a compound and polymorphs thereof, which compound is an inhibitor of kinase activity.
摘要翻译: 本发明涉及一种化合物和化合物的盐及其多晶型物的多晶型物,该化合物是激酶活性的抑制剂。
-
公开(公告)号:US20130203772A1
公开(公告)日:2013-08-08
申请号:US13879667
申请日:2011-10-25
申请人: Julie Nicole Hamblin , Paul Spencer Jones , Suzanne Elaine Keeling , Joelle Le , Nigel James Parr , Robert David Willacy
发明人: Julie Nicole Hamblin , Paul Spencer Jones , Suzanne Elaine Keeling , Joelle Le , Nigel James Parr , Robert David Willacy
IPC分类号: C07D413/14
CPC分类号: C07D413/14
摘要: The present invention is directed to a polymorph of a compound and salts of a compound and polymorphs thereof, which compound is an inhibitor of kinase activity.
摘要翻译: 本发明涉及一种化合物和化合物的盐及其多晶型物的多晶型物,该化合物是激酶活性的抑制剂。
-
公开(公告)号:US20120220779A1
公开(公告)日:2012-08-30
申请号:US13503867
申请日:2010-11-02
申请人: Claire Frances Crawford , Sandrine Garcia , Jonathan Paul Graham , Sandra Jane Harling , Nicholas Paul Henley , Stephen Andrew Hermitage , John Howard Hutchinson , Trevor Raymond Keel , Andrew Kennedy , Andrew McMurtrie Mason , Mark Simon Scott , Neil Michael Smith , Nicholas Simon Stock , Yuichi Tateno , Leontine Saskia Trouw , Peter Graham Turner , Christopher John Wallis , Robert David Willacy
发明人: Claire Frances Crawford , Sandrine Garcia , Jonathan Paul Graham , Sandra Jane Harling , Nicholas Paul Henley , Stephen Andrew Hermitage , John Howard Hutchinson , Trevor Raymond Keel , Andrew Kennedy , Andrew McMurtrie Mason , Mark Simon Scott , Neil Michael Smith , Nicholas Simon Stock , Yuichi Tateno , Leontine Saskia Trouw , Peter Graham Turner , Christopher John Wallis , Robert David Willacy
IPC分类号: C07D401/14
CPC分类号: C07D403/14
摘要: The present invention provides processes useful for preparing 5-lipoxygenase activating protein (FLAP) inhibitors and their intermediates. In particular, processes for preparing 3-[3-(tert-butylsulfanyl)-1-[4-(6-ethoxy-pyridin-3-yl)benzyl]-5-(5-methyl-pyridin-2-yl-methoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid, the anhydrous Form C polymorph of sodium 3-[3-(tert-butylsulfanyl)-1-[4-(6-ethoxy-pyridin-3-yl)benzyl]-5-(5-methyl-pyridin-2-yl-methoxy)-1H-indol-2-yl]-2,2-dimethyl-propionate, and intermediates useful in said processes are provided.
摘要翻译: 本发明提供了可用于制备5-脂氧合酶活化蛋白(FLAP)抑制剂及其中间体的方法。 特别地,制备3- [3-(叔丁基硫烷基)-1- [4-(6-乙氧基 - 吡啶-3-基)苄基] -5-(5-甲基 - 吡啶-2-基 - 甲氧基 )-1H-吲哚-2-基] -2,2-二甲基 - 丙酸,3- [3-(叔丁基硫烷基)-1- [4-(6-乙氧基 - 吡啶-2-基) 吡啶-3-基)苄基] -5-(5-甲基 - 吡啶-2-基 - 甲氧基)-1H-吲哚-2-基] -2,2-二甲基 - 丙酸酯,以及可用于所述方法的中间体。
-
-
-
-